- Forrás: health.ec.europa.eu, 11 June 2026 - EC
Hungary continues to lag significantly behind other European Union countries in terms of healthcare, according to a recent country report by the European Commission.
Select your language
Hungary continues to lag significantly behind other European Union countries in terms of healthcare, according to a recent country report by the European Commission.
The pharmaceutical and biomedical sector represents one of the highest value-added industrial segments and a strategic priority for the Hungarian economy. The local production landscape features the coexistence of historic national champions with an international reach, such as Gedeon Richter, Béres Pharmaceuticals, and Meditop, alongside major multinational groups including AstraZeneca, Pfizer, Novartis, and Servier.
Appearing before Parliament’s health committee on Monday, the minister-designate pledged a fundamentally new approach: care that is measurable and transparent, a renewed emphasis on primary care and professional bodies, and an additional 500 billion forints in annual funding for the sector.
János Révész, Hungary’s national hospital director-general, has announced his resignation just one day before the incoming Tisza-led government takes office, saying the country’s changing political leadership should be free to appoint its own healthcare chief.
Hungary’s healthcare system could undergo one of its most significant transformations in decades under the programme of the Tisza Party, with changes expected to affect millions of patients and medical professionals alike.